FIGURE 3: mIDH-associated hypermethylation is not replicated by TET2 mutation in AML patients. (A) Principal Component Analysis of TET2 WT and TET2 mutant AML patients using all probes retained after quality filtering. No clear separation of the two patient groups was achieved. (B) Comparison of AML patients with and without TET2 mutations by scatterplot. The average beta value of each 450K probe in the two groups is represented as a single dot. DMPs are colored in blue. IDH mutant patients were removed from the analysis. (C) Boxplot of average beta values of all probes in TET2 WT and TET2 mutant AML patients (P=0.52).